{"id":"fluoroestradiol-f-18","rwe":[],"_fda":{"id":"fd28ffaf-5b17-43e7-bc91-fd623819340e","set_id":"b2c2a2df-cf3e-4a29-a033-231ed5a94b58","openfda":{"nui":["N0000177914","N0000175869"],"unii":["T32277KB09"],"route":["INTRAVENOUS"],"spl_id":["fd28ffaf-5b17-43e7-bc91-fd623819340e"],"brand_name":["CERIANNA"],"spl_set_id":["b2c2a2df-cf3e-4a29-a033-231ed5a94b58"],"package_ndc":["72874-001-01"],"product_ndc":["72874-001"],"generic_name":["FLUOROESTRADIOL F 18"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["FLUOROESTRADIOL F-18"],"pharm_class_epc":["Radioactive Diagnostic Agent [EPC]"],"pharm_class_moa":["Positron Emitting Activity [MoA]"],"manufacturer_name":["GE Healthcare Inc."],"application_number":["NDA212155"],"is_original_packager":[true]},"version":"27","pregnancy":["8.1 Pregnancy Risk Summary All radiopharmaceuticals, including CERIANNA, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of radiation dose. Advise a pregnant woman of the potential risks of fetal exposure to radiation from administration of CERIANNA. There are no available data on CERIANNA use in pregnant women. No animal reproduction studies using fluoroestradiol F 18 have been conducted to evaluate its effect on female reproduction and embryo-fetal development. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively."],"description":["11 DESCRIPTION 11.1 Chemical Characteristics CERIANNA contains fluoroestradiol fluorine 18 (F 18), a synthetic estrogen analog. Chemically, fluoroestradiol F 18 is [18F]16α-fluoro-3,17β-diol-estratriene-1,3,5(10). The molecular weight is 289.37, and the structural formula is: CERIANNA is a sterile, clear, colorless solution for intravenous injection, with an osmolarity of 340 mOsm. Its pH ranges between 5.5 to 8.0. The composition of the final product in 40 mL solution is fluoroestradiol no more than 5 mcg, fluoroestradiol F 18 148 MBq/mL to 3,700 MBq/mL (4 mCi/mL to 100 mCi/mL), sodium ascorbate 0.44% w/v in sodium chloride 0.9% w/v, and ethanol no more than 3.2% w/v. Chemical Structure 11.2 Physical Characteristics CERIANNA is radiolabeled with F 18, a cyclotron produced radionuclide that decays by positron emission to stable oxygen 18 with a half-life of 109.8 minutes. The principal photons useful for diagnostic imaging are the coincident pair of 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron (Table 2). Table 2. Principal Radiation Produced From Decay of Fluorine 18 Radiation Radiation Energy Level (keV) % Abundance Positron 249.8 96.9 Gamma 511 193.5 11.3 External Radiation The point source air-kerma coefficient for F 18 is 3.75 × 10 -17 Gy m 2 / (Bq s). The first half-value thickness of lead (Pb) for F 18 gamma rays is approximately 6 mm. The relative reduction of radiation emitted by F 18 that results from various thicknesses of lead shielding is shown in Table 3. The use of 8 cm Pb decreases the radiation transmission (i.e., exposure) by a factor of about 10,000. Table 3. Radiation Attenuation of 511 keV Gamma Rays by Lead Shielding Shield Thickness cm of Lead (Pb) Coefficient of Attenuation 0.6 0.5 2 0.1 4 0.01 6 0.001 8 0.0001"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied CERIANNA is supplied in a 50 mL multiple-dose glass vial (NDC 72874-001-01) containing a clear, colorless injection solution at a strength of 148 MBq/mL to 3,700 MBq/mL (4 mCi/mL to 100 mCi/mL) fluoroestradiol F 18 at the end of synthesis. Each vial contains multiple doses and is enclosed in a shield container to minimize external radiation exposure. 16.2 Storage and Handling Storage Store CERIANNA at controlled room temperature (USP) 20°C to 25°C (68°F to 77°F). Store CERIANNA upright in the original container with radiation shielding. The expiration date and time are provided on the container label. Use CERIANNA within 12 hours from the time of the end of synthesis. Handling This preparation is approved for use by persons under license by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State."],"geriatric_use":["8.5 Geriatric Use Clinical studies of fluoroestradiol F 18 injection did not reveal any difference in pharmacokinetics or biodistribution in patients aged 65 and over."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of CERIANNA in pediatric patients have not been established."],"effective_time":"20260112","clinical_studies":["14 CLINICAL STUDIES The effectiveness of CERIANNA for detecting ER-positive non-primary breast cancer lesions was evaluated based on published study reports of fluoroestradiol F 18. Study 1 (NCT01986569) enrolled 90 women (median age 55 years, 39% premenopausal) with histologically confirmed invasive breast cancer. The patients had first known or suspected recurrence of treated breast cancer or stage IV metastatic breast cancer. Recent biopsy of lesions outside of bone and areas with high physiologic fluoroestradiol F 18 uptake was also required [see Dosage and Administration (2.5) ] . Patients concurrently using estrogen receptor modulators or fulvestrant discontinued them 60 days prior to fluoroestradiol F 18 administration. Concurrent use of aromatase inhibitors was permitted. Three image readers were blinded to all clinical information, except for the location of the largest biopsied lesion, for which pathologists independently provided an Allred score (0 to 8). The image readers scored the intensity of FES uptake on a three-point scale relative to normal biodistribution as either \"decreased,\" \"equivocal,\" or \"increased\" (1 to 3). Image reader performance for distinguishing between ER-positive and ER-negative fluoroestradiol F 18 uptake was compared to biopsy in 85 patients. Of the 47 patients with positive biopsy (Allred score ≥ 3), 36 were positive on imaging (majority reader score = 3). Ten of 11 patients with false negative imaging had Allred scores between 3 and 6 [see Warnings and Precautions (5.1) ] . Of the 38 patients with negative biopsy, all 38 were negative on imaging. Study 2 (NCT00602043) in 13 patients showed similar results."],"pharmacodynamics":["12.2 Pharmacodynamics The relationship between fluoroestradiol F18 plasma concentrations and image interpretation has not been studied. Fluoroestradiol F18 uptake measured by PET in human tumors is directly proportional to tumor ER expression measured by in vitro assays."],"pharmacokinetics":["12.3 Pharmacokinetics Distribution After intravenous injection, 95% of fluoroestradiol F 18 is bound to plasma proteins. Fluoroestradiol F 18 distributes primarily to hepatobiliary system, and also to small and large intestines, heart wall, blood, kidney, uterus and bladder. Metabolism Fluoroestradiol F 18 is metabolized in the liver. At 20 minutes after injection, approximately 20% of circulating radioactivity in the plasma is in the form of non-metabolized fluoroestradiol F 18. At 2 hours after injection, circulating fluoroestradiol F 18 levels are less than 5% of peak concentration. Excretion Elimination is by biliary and urinary excretion."],"adverse_reactions":["6 ADVERSE REACTIONS Reported adverse reactions include: injection-site pain and dysgeusia ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 1-800-654-0118 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of CERIANNA was evaluated from published clinical studies of 1,207 patients with breast cancer receiving at least one fluoroestradiol F 18 administration. The following adverse reactions occurred at a rate < 1%: General disorders : injection-site pain Neurological and gastrointestinal disorders : dysgeusia"],"contraindications":["4 CONTRAINDICATIONS None . None. ( 4 )"],"description_table":["
Table 2. Principal Radiation Produced From Decay of Fluorine 18 Radiation
RadiationEnergy Level (keV)% Abundance
Positron249.896.9
Gamma511193.5
","
Table 3. Radiation Attenuation of 511 keV Gamma Rays by Lead Shielding
Shield Thickness cm of Lead (Pb)Coefficient of Attenuation
0.60.5
20.1
40.01
60.001
80.0001
"],"drug_interactions":["7 DRUG INTERACTIONS Drugs that bind to the estrogen receptor (ER) may compete with the binding of fluoroestradiol F 18 and may reduce the detection of ER-positive lesions with CERIANNA. Before administering CERIANNA, discontinue drugs that bind to the ER, such as SERMs and SERDs, for at least 5 biological half-lives (e.g., elacestrant for 11 days, tamoxifen for 8 weeks, and fulvestrant for 28 weeks) [see Dosage and Administration (2.3) ] . Before administering CERIANNA, discontinue drugs that bind to the ER, such as SERMs and SERDs, for at least 5 biological half-lives (e.g., elacestrant for 11 days, tamoxifen for 8 weeks, and fulvestrant for 28 weeks). ( 2.3 , 7 )"],"mechanism_of_action":["12.1 Mechanism of Action Fluoroestradiol F 18 binds ER. The following binding affinity: Kd = 0.13 ± 0.02 nM, Bmax = 1901 ± 89 fmol/mg, and IC 50 = 0.085 nM, was determined in an ER-positive human breast cancer cell line (MCF-7)."],"storage_and_handling":["16.2 Storage and Handling Storage Store CERIANNA at controlled room temperature (USP) 20°C to 25°C (68°F to 77°F). Store CERIANNA upright in the original container with radiation shielding. The expiration date and time are provided on the container label. Use CERIANNA within 12 hours from the time of the end of synthesis. Handling This preparation is approved for use by persons under license by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Fluoroestradiol F 18 binds ER. The following binding affinity: Kd = 0.13 ± 0.02 nM, Bmax = 1901 ± 89 fmol/mg, and IC 50 = 0.085 nM, was determined in an ER-positive human breast cancer cell line (MCF-7). 12.2 Pharmacodynamics The relationship between fluoroestradiol F18 plasma concentrations and image interpretation has not been studied. Fluoroestradiol F18 uptake measured by PET in human tumors is directly proportional to tumor ER expression measured by in vitro assays. 12.3 Pharmacokinetics Distribution After intravenous injection, 95% of fluoroestradiol F 18 is bound to plasma proteins. Fluoroestradiol F 18 distributes primarily to hepatobiliary system, and also to small and large intestines, heart wall, blood, kidney, uterus and bladder. Metabolism Fluoroestradiol F 18 is metabolized in the liver. At 20 minutes after injection, approximately 20% of circulating radioactivity in the plasma is in the form of non-metabolized fluoroestradiol F 18. At 2 hours after injection, circulating fluoroestradiol F 18 levels are less than 5% of peak concentration. Excretion Elimination is by biliary and urinary excretion."],"indications_and_usage":["1 INDICATIONS AND USAGE CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. CERIANNA is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. ( 1 ) Limitations of Use Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR). ( 1 , 5.1 ) Limitations of Use Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR)."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Risk of Misdiagnosis . Do not use CERIANNA in lieu of biopsy when biopsy is indicated in patients with recurrent or metastatic breast cancer. Pathology or clinical characteristics that suggest a patient may benefit from systemic hormone therapy should take precedence over a discordant negative CERIANNA scan. ( 5.1 ) Radiation Risks . Ensure safe drug handling and patient preparation procedures to protect patients and health care providers from unintentional radiation exposure. ( 2.1 , 2.3 , 5.2 ) 5.1 Risk of Misdiagnosis Inadequate Tumor Characterization and Other ER-Positive Pathology Breast cancer may be heterogeneous within patients and across time. CERIANNA images ER and is not useful for imaging other receptors such as HER2 and PR. The uptake of fluoroestradiol F 18 is not specific for breast cancer and may occur in a variety of ER-positive tumors that arise outside of the breast, including from the uterus and ovaries. Do not use CERIANNA in lieu of biopsy when biopsy is indicated in patients with recurrent or metastatic breast cancer. False Negative CERIANNA Scan A negative CERIANNA scan does not rule out ER-positive breast cancer [see Clinical Studies (14) ] . Pathology or clinical characteristics that suggest a patient may benefit from systemic hormone therapy should take precedence over a discordant negative CERIANNA scan. 5.2 Radiation Risks Diagnostic radiopharmaceuticals, including CERIANNA, expose patients to radiation [see Dosage and Administration (2.6) ] . Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe drug handling and patient preparation procedures to protect patients and health care providers from unintentional radiation exposure [see Dosage and Administration (2.1) and (2.3) ] ."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis No long-term studies in animals were performed to evaluate the carcinogenic potential of CERIANNA. Mutagenesis Fluoroestradiol was evaluated by in vitro bacterial reverse mutation assay (Ames test) and in vitro L5178Y/TK+/- mouse lymphoma mutagenesis assay. Fluoroestradiol was negative for genotoxicity by Ames test at up to 1.25 µg per plate for 5 tester strains ( Salmonella typhimurium tester strains TA98, TA100, TA1535 and TA1537 and Escherichia Coli tester strain WP2 uvrA) in the presence or absence of S9 metabolic activation. Fluoroestradiol was negative for genotoxicity by L5178Y/TK+/- mouse lymphoma mutagenesis assay at up to 8 ng/mL in the absence or presence of S9 metabolic activation. Potential in vivo genotoxicity of fluoroestradiol was evaluated in a rat micronucleus assay. In this assay, fluoroestradiol did not increase the number of micronucleated polychromatic erythrocytes (MN-PCEs) at 51 µg/kg/day, when given for 14 consecutive days. However, CERIANNA has the potential to be mutagenic because of the F 18 radioisotope. Impairment of Fertility No studies in animals have been performed to evaluate potential impairment of fertility in males or females."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Radiation Risks Advise patients of the radiation risks of CERIANNA [see Warnings and Precautions (5.2) ] . Instruct patients to drink water to ensure adequate hydration prior to administration of CERIANNA and to continue drinking and voiding frequently during the first hours following administration to reduce radiation exposure [see Dosage and Administration (2.3) ] . Pregnancy Advise a pregnant woman of the potential risks of fetal exposure to radiation doses with CERIANNA [see Use in Specific Populations (8.1) ] . Lactation Advise a lactating woman to avoid breastfeeding for 4 hours after CERIANNA administration in order to minimize radiation exposure to a breastfed infant [see Use in Specific Populations (8.2) ]."],"spl_unclassified_section":["© 2025 GE HealthCare Distributed by GE Healthcare Inc., Arlington Heights, IL 60004 U.S.A. GE is a trademark of General Electric Company used under trademark license."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Recommended dose is 222 MBq (6 mCi), with a range of 111 MBq to 222 MBq (3 mCi to 6 mCi), administered as an intravenous injection over 1 to 2 minutes. ( 2.2 ) Recommended imaging start time is 80 minutes (range 20 minutes to 80 minutes) after drug administration. ( 2.4 ) See full prescribing information for additional preparation, administration, imaging, and radiation dosimetry information. ( 2 ) 2.1 Radiation Safety - Drug Handling CERIANNA is a radioactive drug. Only authorized persons qualified by training and experience should receive, use, and administer CERIANNA. Handle CERIANNA with appropriate safety measures to minimize radiation exposure during administration [see Warnings and Precautions (5.2) ] . Use waterproof gloves and effective radiation shielding, including syringe shields, when preparing and handling CERIANNA. 2.2 Recommended Dosage and Administration Instructions Recommended Dosage The recommended amount of radioactivity to be administered for PET imaging is 222 MBq (6 mCi), with a range of 111 MBq to 222 MBq (3 mCi to 6 mCi), administered as a single intravenous injection of 10 mL or less over 1 to 2 minutes. Preparation and Administration For patient preparation instructions, see Dosage and Administration 2.3 . Use aseptic technique and radiation shielding when withdrawing and administering CERIANNA. Visually inspect the radiopharmaceutical solution. Do not use if it contains particulate matter or if it is cloudy or discolored (CERIANNA is a clear, colorless solution). CERIANNA may be diluted with 0.9% Sodium Chloride Injection, USP. Assay the dose in a suitable dose calibrator prior to administration. Post-Administration Instructions Follow the CERIANNA injection with an intravenous flush of 0.9% Sodium Chloride injection, USP. Dispose of any unused CERIANNA in compliance with applicable regulations. 2.3 Patient Preparation Assessment for Drug Interactions Before administering CERIANNA, discontinue drugs that bind to ER (e.g., selective estrogen receptor modulators (SERMs) and selective estrogen receptor down-regulators (SERDs)) [see Drug Interactions (7) ] . Patient Hydration and Voiding Instruct patients to drink water to ensure adequate hydration prior to administration of CERIANNA and to continue drinking and voiding frequently during the first hours following administration to reduce radiation exposure. Pregnancy Status Assessment of pregnancy status is recommended in females of reproductive potential before administering CERIANNA. 2.4 Image Acquisition Position the patient supine with arms above the head, if possible. The recommended start time for image acquisition is 80 minutes after the intravenous administration of CERIANNA. Scan duration adapted from the range of 20 minutes to 30 minutes and imaging start times adapted within the range of 20 minutes to 80 minutes may be customized according to the equipment used and patient and tumor characteristics for optimal image quality. 2.5 Image Interpretation Uptake of fluoroestradiol F 18 depends on ER density and function in tumors and physiologic tissue, including in liver, ovary, and uterus. Detection of ER-positive tumors should be based on comparison with tissue background outside of organs with high physiologic uptake and regions with high activity due to hepatobiliary and urinary excretion. 2.6 Radiation Dosimetry Radiation absorbed dose estimates are shown in Table 1 for organs and tissues of adults from intravenous administration of CERIANNA. The radiation effective dose resulting from administration of 222 MBq (6 mCi) of CERIANNA to an adult weighing 70 kg is estimated to be 4.9 mSv. Critical organs include the liver, gallbladder, and uterus. When PET/CT is performed, exposure to radiation will increase by an amount dependent on the settings used for the CT acquisition. Table 1. Estimated Radiation Absorbed Doses in Various Organs/Tissues in Adults Who Received FLUOROESTRADIOL F 18 Organ Mean Absorbed Dose Per Unit of Activity Administered (mGy/MBq) Adrenals 0.023 Brain 0.01 Breasts 0.009 Gallbladder 0.102 Lower large intestine 0.012 Small intestine 0.027 Stomach 0.014 Upper large intestine 0.03 Heart wall 0.026 Kidney 0.035 Liver 0.126 Lungs 0.017 Muscle 0.021 Ovaries 0.018 Pancreas 0.023 Red Marrow 0.013 Bone surface 0.014 Skin 0.005 Spleen 0.015 Testes 0.012 Thymus 0.014 Thyroid 0.012 Urinary bladder 0.05 Uterus 0.039 Lens 0.009 Effective dose = 0.022 mSv/MBq"],"spl_product_data_elements":["CERIANNA FLUOROESTRADIOL F 18 FLUOROESTRADIOL F-18 FLUOROESTRADIOL F-18 SODIUM ASCORBATE SODIUM CHLORIDE ALCOHOL"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: clear, colorless solution in a multiple-dose vial containing 148 MBq/mL to 3,700 MBq/mL (4 mCi/mL to 100 mCi/mL) of fluoroestradiol F 18 at end of synthesis. Injection: 148 MBq/mL to 3,700 MBq/mL (4 mCi/mL to 100 mCi/mL) of fluoroestradiol F 18 in a multiple-dose vial. ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Interrupt breastfeeding. Advise a lactating woman to avoid breastfeeding for 4 hours after CERIANNA administration. ( 8.2 ) 8.1 Pregnancy Risk Summary All radiopharmaceuticals, including CERIANNA, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of radiation dose. Advise a pregnant woman of the potential risks of fetal exposure to radiation from administration of CERIANNA. There are no available data on CERIANNA use in pregnant women. No animal reproduction studies using fluoroestradiol F 18 have been conducted to evaluate its effect on female reproduction and embryo-fetal development. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. 8.2 Lactation Risk Summary There are no data on the presence of fluoroestradiol F 18 in human milk, or its effects on the breastfed infant or milk production. Lactation studies have not been conducted in animals. Advise a lactating woman to avoid breastfeeding for 4 hours after CERIANNA administration in order to minimize radiation exposure to a breastfed infant. 8.4 Pediatric Use The safety and effectiveness of CERIANNA in pediatric patients have not been established. 8.5 Geriatric Use Clinical studies of fluoroestradiol F 18 injection did not reveal any difference in pharmacokinetics or biodistribution in patients aged 65 and over."],"dosage_and_administration_table":["
Table 1. Estimated Radiation Absorbed Doses in Various Organs/Tissues in Adults Who Received FLUOROESTRADIOL F 18
OrganMean Absorbed Dose Per Unit of Activity Administered (mGy/MBq)
Adrenals0.023
Brain0.01
Breasts0.009
Gallbladder0.102
Lower large intestine0.012
Small intestine0.027
Stomach0.014
Upper large intestine0.03
Heart wall0.026
Kidney0.035
Liver0.126
Lungs0.017
Muscle0.021
Ovaries0.018
Pancreas0.023
Red Marrow0.013
Bone surface0.014
Skin0.005
Spleen0.015
Testes0.012
Thymus0.014
Thyroid0.012
Urinary bladder0.05
Uterus0.039
Lens0.009
Effective dose = 0.022 mSv/MBq
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 50 mL Vial Label CERIANNA™ (fluoroestradiol F 18) Injection 148 MBq/mL to 3,700 MBq/mL (4 mCi/mL to 100 mCi/mL) @ End of Synthesis For Intravenous Use Only Multiple-Dose Vial Rx ONLY Date of manufacture: Expiration date & time:__________; ______hr:min Lot# _______________________________________ Volume: ________ mL Store at 20°C to 25°C (68°F to 77°F) Store upright in a shielded container Do not use if cloudy or if it contains particulate matter Contains: 148 MBq/mL to 3,700 MBq/mL (4 mCi/mL to 100 mCi/mL) of no-carrier added fluoroestradiol F 18 @ EOS; sodium ascorbate 0.44% w/v in sodium chloride 0.9% w/v and ethanol no more than 3.2% w/v Usual dosage: See prescribing information CAUTION: RADIOACTIVE MATERIAL Dist.by: GE Healthcare, Inc., Arlington Heights, IL 60004 USA GE is a trademark of General Electric Company used under trademark license. 100112-0B PRINCIPAL DISPLAY PANEL - 50 mL Vial Label","PRINCIPAL DISPLAY PANEL - 50 mL Vial Shield Label NDC 72874-001-01 Multiple-Dose Vial CERIANNA™ (fluoroestradiol F 18) Injection 148 MBq/mL to 3,700 MBq/mL (4 mCi/mL to 100 mCi/mL) @ EOS* For Intravenous Use Only Sterile, Non-pyrogenic Diagnostic Date/time of calibration: _____________; ________hr:min Expiration date & time: _____________; ________hr:min Volume: _______________________ mL Lot # ________________________ Concentration: ___________mCi/mL at time of calibration Total Activity: ____________mCi at time of calibration Contains: 148 MBq/mL to 3,700 MBq/mL (4 mCi/mL to 100 mCi/mL) of no-carrier added fluoroestradiol F 18 @ EOS*; sodium ascorbate 0.44% w/v in sodium chloride 0.9% w/v and ethanol no more than 3.2% w/v Usual dosage: See prescribing information Do not use if cloudy or if it contains particulate matter *EOS = End of Synthesis CAUTION: RADIOACTIVE MATERIAL Expires 12 hours after EOS* Store at 20°C to 25°C (68°F to 77°F) Store upright in a shielded container Aseptically withdraw and handle doses [18F] Half-Life = 109.8 minutes Calculate correct dosage from date and time of calibration Dist. by: GE Healthcare, Inc. Arlington Heights, IL 60004 USA GE is a trademark of General Electric Company used under trademark license. 100113-0B Rx ONLY PRINCIPAL DISPLAY PANEL - 50 mL Vial Shield Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis No long-term studies in animals were performed to evaluate the carcinogenic potential of CERIANNA. Mutagenesis Fluoroestradiol was evaluated by in vitro bacterial reverse mutation assay (Ames test) and in vitro L5178Y/TK+/- mouse lymphoma mutagenesis assay. Fluoroestradiol was negative for genotoxicity by Ames test at up to 1.25 µg per plate for 5 tester strains ( Salmonella typhimurium tester strains TA98, TA100, TA1535 and TA1537 and Escherichia Coli tester strain WP2 uvrA) in the presence or absence of S9 metabolic activation. Fluoroestradiol was negative for genotoxicity by L5178Y/TK+/- mouse lymphoma mutagenesis assay at up to 8 ng/mL in the absence or presence of S9 metabolic activation. Potential in vivo genotoxicity of fluoroestradiol was evaluated in a rat micronucleus assay. In this assay, fluoroestradiol did not increase the number of micronucleated polychromatic erythrocytes (MN-PCEs) at 51 µg/kg/day, when given for 14 consecutive days. However, CERIANNA has the potential to be mutagenic because of the F 18 radioisotope. Impairment of Fertility No studies in animals have been performed to evaluate potential impairment of fertility in males or females."]},"tags":[{"label":"Radioactive Diagnostic Agent","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Estrogen receptor","category":"target"},{"label":"ESR1","category":"gene"},{"label":"V09IX11","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Positron emission tomography","category":"indication"},{"label":"Ge Healthcare","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"SERMs (Selective Estrogen Receptor Modulators)","severity":"major","mechanism":"Competitive binding to the estrogen receptor (ER)","management":"Discontinue for at least 5 biological half-lives before administering CERIANNA","clinicalEffect":"May reduce the detection of ER-positive lesions with CERIANNA"},{"drug":"SERDs (Selective Estrogen Receptor Degraders)","severity":"major","mechanism":"Competitive binding to the estrogen receptor (ER)","management":"Discontinue for at least 5 biological half-lives before administering CERIANNA","clinicalEffect":"May reduce the detection of ER-positive lesions with CERIANNA"},{"drug":"elacestrant","severity":"major","mechanism":"Competitive binding to the estrogen receptor (ER)","management":"Discontinue for at least 11 days before administering CERIANNA","clinicalEffect":"May reduce the detection of ER-positive lesions with CERIANNA"},{"drug":"tamoxifen","severity":"major","mechanism":"Competitive binding to the estrogen receptor (ER)","management":"Discontinue for at least 8 weeks before administering CERIANNA","clinicalEffect":"May reduce the detection of ER-positive lesions with CERIANNA"},{"drug":"fulvestrant","severity":"major","mechanism":"Competitive binding to the estrogen receptor (ER)","management":"Discontinue for at least 28 weeks before administering CERIANNA","clinicalEffect":"May reduce the detection of ER-positive lesions with CERIANNA"}],"commonSideEffects":[{"effect":"injection-site pain","drugRate":"1%","severity":"mild","_validated":true},{"effect":"dysgeusia","drugRate":"1%","severity":"mild","_validated":true}],"specialPopulations":{"Lactation":"There are no data on the presence of fluoroestradiol 18 in human milk, or its effects on the breastfed infant or milk production. Lactation studies have not been conducted in animals. Advise lactating woman to avoid breastfeeding for hours after CERIANNA administration in order to minimize radiation exposure to breastfed infant.","Pregnancy":"All radiopharmaceuticals, including CERIANNA, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of radiation dose. Advise pregnant woman of the potential risks of fetal exposure to radiation from administration of CERIANNA. There are no available data on CERIANNA use in pregnant women. No animal reproduction studies using fluoroestradiol 18 have been conducted to evaluate its effect on female reproduction and embryo-fetal development.The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.","Paediatric use":"The safety and effectiveness of CERIANNA in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"GE HealthCare","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FLUOROESTRADIOL F-18","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:26:04.785347+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T03:26:52.544592+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:26:10.333660+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLUOROESTRADIOL F-18","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:26:10.616864+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:26:00.904528+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:26:00.904566+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:26:44.982428+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:26:00.904573+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:26:38.166033+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594261/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:26:11.950837+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA212155","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:26:00.904577+00:00"}},"allNames":"cerianna","offLabel":[],"synonyms":["fluoroestradiol F-18","fluoroestradiol F 18","fluoroestradiol","cerianna"],"timeline":[{"date":"2020-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from ZIONEXA to Ge Healthcare"},{"date":"2020-05-20","type":"positive","source":"DrugCentral","milestone":"FDA approval (Zionexa)"}],"aiSummary":"Cerianna, a fluorine-18 labeled estradiol developed by GE HealthCare, is currently marketed for the detection of ER-positive lesions in breast cancer. Its key strength lies in its mechanism of action, which allows for precise imaging of estrogen receptors through positron emission tomography, providing a unique advantage in the diagnosis of breast cancer. The primary risk is the presence of several same-class competitors, including off-patent sodium fluoride F-18, which may limit market share and revenue potential.","brandName":"Cerianna","ecosystem":[{"indication":"Positron emission tomography","otherDrugs":[{"name":"AMMONIA N-13","slug":"ammonia-n-13","company":"Feinstein"},{"name":"Florbetapir F-18","slug":"florbetapir-f-18","company":"Avid Radiopharms Inc"},{"name":"Flutemetamol (18F)","slug":"flutemetamol-(18f)","company":"Ge Healthcare"},{"name":"Gallium Ga 68 dotatate","slug":"gallium-ga-68-dotatate","company":"Advanced Accelerator Applications Usa Inc"}],"globalPrevalence":null}],"mechanism":{"target":"Estrogen receptor","novelty":"Follow-on","targets":[{"gene":"ESR1","source":"DrugCentral","target":"Estrogen receptor","protein":"Estrogen receptor"}],"moaClass":"Positron Emitting Activity","modality":"Small Molecule","drugClass":"Radioactive Diagnostic Agent [EPC]","explanation":"Imagine your body's cells have locks on them, and estrogen receptors are the keys that fit into those locks. Cerianna is a special key that has a tiny bit of radioactive material attached to it, which allows doctors to see where the estrogen receptors are located in the body using a special camera.","oneSentence":"Cerianna works by binding to estrogen receptors in the body, allowing for imaging of these receptors through positron emission tomography.","technicalDetail":"Cerianna is a small molecule radioactive diagnostic agent that selectively binds to estrogen receptors through high-affinity interactions, enabling visualization of estrogen receptor expression via PET imaging.","_target_confidence":0.5},"commercial":{"launchDate":"2020","_launchSource":"DrugCentral (FDA 2020-05-20, ZIONEXA)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5395","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FLUOROESTRADIOL%20F-18","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLUOROESTRADIOL F-18","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T02:41:46.274977","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:26:52.545140+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"iobenguane (123I)","drugSlug":"iobenguane-(123i)","fdaApproval":"2008-09-19","relationship":"same-class"},{"drugName":"iobenguane (131I)","drugSlug":"iobenguane-(131i)","fdaApproval":"1994-03-25","relationship":"same-class"},{"drugName":"fludeoxyglucose (18F)","drugSlug":"fludeoxyglucose-(18f)","fdaApproval":"1994-08-19","relationship":"same-class"},{"drugName":"fluorodopa (18F)","drugSlug":"fluorodopa-(18f)","fdaApproval":"2019-10-10","relationship":"same-class"},{"drugName":"sodium fluoride F-18","drugSlug":"sodium-fluoride-f-18","fdaApproval":"1972-02-24","genericCount":23,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"gallium (68Ga) edotreotide","drugSlug":"gallium-(68ga)-edotreotide","fdaApproval":"2019-08-21","relationship":"same-class"},{"drugName":"fluciclovine (18F)","drugSlug":"fluciclovine-(18f)","fdaApproval":"2016-05-27","relationship":"same-class"},{"drugName":"methionine","drugSlug":"methionine","fdaApproval":"","relationship":"same-class"},{"drugName":"gallium (68Ga) gozetotide","drugSlug":"gallium-(68ga)-gozetotide","fdaApproval":"2020-12-01","relationship":"same-class"},{"drugName":"copper dotatate Cu-64","drugSlug":"copper-dotatate-cu-64","fdaApproval":"2020-09-03","relationship":"same-class"}],"genericName":"fluoroestradiol f-18","indications":{"approved":[{"id":"fluoroestradiol-f-18-detection-of-er-positive-lesio","name":"Detection of ER-positive lesions in breast cancer","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with recurrent or metastatic breast cancer","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with recurrent or metastatic breast cancer","diagnosticRequired":"Tissue biopsy to confirm recurrence and ER status","brandNameForIndication":"Cerianna"}],"offLabel":[],"pipeline":[]},"currentOwner":"Ge Healthcare","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"iobenguane-(123i)","brandName":"iobenguane (123I)","genericName":"iobenguane (123I)","approvalYear":"2008","relationship":"same-class"},{"drugId":"iobenguane-(131i)","brandName":"iobenguane (131I)","genericName":"iobenguane (131I)","approvalYear":"1994","relationship":"same-class"},{"drugId":"fludeoxyglucose-(18f)","brandName":"fludeoxyglucose (18F)","genericName":"fludeoxyglucose (18F)","approvalYear":"1994","relationship":"same-class"},{"drugId":"fluorodopa-(18f)","brandName":"fluorodopa (18F)","genericName":"fluorodopa (18F)","approvalYear":"2019","relationship":"same-class"},{"drugId":"sodium-fluoride-f-18","brandName":"sodium fluoride F-18","genericName":"sodium fluoride F-18","approvalYear":"1972","relationship":"same-class"},{"drugId":"gallium-(68ga)-edotreotide","brandName":"gallium (68Ga) edotreotide","genericName":"gallium (68Ga) edotreotide","approvalYear":"2019","relationship":"same-class"},{"drugId":"fluciclovine-(18f)","brandName":"fluciclovine (18F)","genericName":"fluciclovine (18F)","approvalYear":"2016","relationship":"same-class"},{"drugId":"methionine","brandName":"methionine","genericName":"methionine","approvalYear":"","relationship":"same-class"},{"drugId":"gallium-(68ga)-gozetotide","brandName":"gallium (68Ga) gozetotide","genericName":"gallium (68Ga) gozetotide","approvalYear":"2020","relationship":"same-class"},{"drugId":"copper-dotatate-cu-64","brandName":"copper dotatate Cu-64","genericName":"copper dotatate Cu-64","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01986569","phase":"PHASE3","title":"Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","isPivotal":true,"startDate":"2013-11","conditions":["Recurrent Breast Cancer","Stage IV Breast Cancer"],"enrollment":93,"completionDate":"2016-11"},{"nctId":"NCT02398773","phase":"PHASE2","title":"FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-04","conditions":["HER2/Neu Negative","Progesterone Receptor Negative","Progesterone Receptor Positive","Stage IV Breast Cancer AJCC v6 and v7"],"enrollment":99,"completionDate":"2026-03-31"},{"nctId":"NCT07112053","phase":"PHASE2","title":"A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-11-17","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Metastatic HER2-Negative Breast Carcinoma","Metastatic Hormone Receptor-Positive Breast Carcinoma"],"enrollment":40,"completionDate":"2028-12-31"},{"nctId":"NCT04692103","phase":"PHASE2","title":"Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-07-10","conditions":["Estrogen Receptor Positive","Primary or Recurrent Breast Carcinoma","Stage IV Breast Cancer AJCC v6 and v7"],"enrollment":2,"completionDate":"2041-04-30"},{"nctId":"NCT07314073","phase":"PHASE2","title":"[18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-24","conditions":["Stage III Breast Cancer"],"enrollment":85,"completionDate":"2029-12-31"},{"nctId":"NCT06695039","phase":"PHASE2","title":"Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in ER-positive Breast Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2024-11-18","conditions":["Breast Cancer Invasive"],"enrollment":71,"completionDate":"2025-10-02"},{"nctId":"NCT06260033","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-23","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Estrogen Receptor-Positive Breast Carcinoma","Metastatic Breast Carcinoma"],"enrollment":18,"completionDate":"2026-10-29"},{"nctId":"NCT05960201","phase":"PHASE2","title":"Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in Invasive Lobular Carcinoma","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2023-08-10","conditions":["Carcinoma, Lobular"],"enrollment":23,"completionDate":"2024-08-20"},{"nctId":"NCT05068726","phase":"","title":"Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients","status":"TERMINATED","sponsor":"GE Healthcare","startDate":"2023-01-05","conditions":["Metastatic Breast Cancer"],"enrollment":51,"completionDate":"2024-06-01"},{"nctId":"NCT04347135","phase":"PHASE1,PHASE2","title":"Evaluating Endometriosis With 16α-(18)F-fluoro-17β-estradiol ([F-18] FES) PET/MRI","status":"WITHDRAWN","sponsor":"Annie (Annie) T. Packard","startDate":"2022-10-07","conditions":["Endometriosis"],"enrollment":0,"completionDate":"2024-04-30"},{"nctId":"NCT02149173","phase":"NA","title":"F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy","status":"TERMINATED","sponsor":"University of Washington","startDate":"2010-09-15","conditions":["Estrogen Receptor Positive","Recurrent Breast Carcinoma","Stage IV Breast Cancer AJCC v6 and v7"],"enrollment":29,"completionDate":"2021-01-13"},{"nctId":"NCT03065712","phase":"PHASE2","title":"Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-02-22","conditions":["Breast Cancer"],"enrollment":0,"completionDate":"2021-02-20"},{"nctId":"NCT00602043","phase":"PHASE2","title":"F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":true,"startDate":"2008-09","conditions":["Estrogen Receptor-positive Breast Cancer","Progesterone Receptor-negative Breast Cancer","Progesterone Receptor-positive Breast Cancer","Recurrent Breast Cancer","Stage IV Breast Cancer"],"enrollment":20,"completionDate":"2014-09"},{"nctId":"NCT01720602","phase":"NA","title":"Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-11","conditions":["Male Breast Cancer","Recurrent Breast Cancer","Stage IV Breast Cancer"],"enrollment":15,"completionDate":"2020-01"},{"nctId":"NCT02374931","phase":"EARLY_PHASE1","title":"18F-FES PET/CT in Imaging Patients With Desmoid Tumors","status":"TERMINATED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2015-04","conditions":["Deep Fibromatosis/Desmoid Tumor","Familial Adenomatous Polyposis"],"enrollment":3,"completionDate":"2017-12"},{"nctId":"NCT01153672","phase":"NA","title":"Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy","status":"COMPLETED","sponsor":"University of Washington","startDate":"2010-11","conditions":["Male Breast Cancer","Recurrent Breast Cancer","Stage IV Breast Cancer"],"enrollment":8,"completionDate":"2016-08-11"},{"nctId":"NCT03266562","phase":"NA","title":"Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2018-09-01","conditions":["Breast Neoplasm"],"enrollment":0,"completionDate":"2019-04-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT01986569","NCT00602043"],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"CERIANNA"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"363734","NDDF":"018375","UNII":"T32277KB09","RXNORM":"2372221","UMLSCUI":"C1831937","chemblId":"CHEMBL4594261","ChEMBL_ID":"CHEMBL4594261","KEGG_DRUG":"D11829","DRUGBANK_ID":"DB15690","PUBCHEM_CID":"10869981","SNOMEDCT_US":"926372005","SECONDARY_CAS_RN":"92817-10-2"},"formularyStatus":[],"originalProduct":{"form":"INJECTION","route":"INTRAVENOUS","company":"Zionexa US Corporation","brandName":"CERIANNA","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2020-","companyName":"Zionexa","relationship":"Original Developer"},{"period":"present","companyName":"Ge Healthcare","relationship":"Current Owner"}],"publicationCount":1,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"V09IX11","allCodes":["V09IX11"]},"biosimilarFilings":[],"originalDeveloper":"Zionexa","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Ge Healthcare","companyId":"ge-healthcare","modality":"Small molecule","firstApprovalDate":"2020","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:26:52.545140+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}